Medical Developments (ASX:MVP) share price hits new 52 week low

The Medical Developments share price is continuing to struggle today.

| More on:
laboratory workers looking disappointed

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price has fallen to a new 52-week low today.

The company hasn't released any news for nearly a fortnight. However, the last time the market heard from Medical Developments, it shared dire news.

Right now, the Medical Developments share price is $3.25, 2.99% lower than its previous close. It marks a new 12-month record low.

Additionally, Medical Developments was dropped from the S&P/ASX 300 Index (ASX: XKO) on Monday night.

Let's take a closer look at the latest from the specialised healthcare company.

Medical Developments struggles on the ASX

The last 2 weeks have been tough for the Medical Developments share price.

First off, the company released its earnings for financial year 2021 (FY21), sending its stock plummeting.

Medical Developments reported it had ended FY21 with a $12.6 million loss. For comparison, it reported a net profit after tax of $379,000 for FY20.

However, the company's revenue increased by 12.1% to 25.6 million in FY21.

Medical Developments also provided a promising outlook for FY22, stating it's looking forward to seeing strong sales growth for the year ending 30 June 2022.

Since the company released its FY21 results, Medical Development's shares have fallen 18.6%.

More recently, the company was dropped from S&P Dow Jones Indices' S&P/ASX 300 Index after Monday's close.

Following the company's removal from the index, Medical Developments' stock fell by 3% on Tuesday.

Medical Developments share price snapshot

Today's fall included, the Medical Developments share price has dropped more than half its value in 2021.

It is currently 51% lower than it was at the start of this year. It is also 41% lower than it was this time last year.

The company has a market capitalisation of around $233 million.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Medical Developments International Limited. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »